FDA Permits New Myeloma Drug

FDA Permits New Myeloma DrugSupporting evidence has spawned the approval from the Food and Drug Administration (FDA). The organization has permitted the usage of immunomodulator pomalidomide (Pomalyst) by patients.

For the patients who suffer from refractory multiple melanomas, FDA has given a green signal to the drug. FDA said that the experiments were performed on the patients who were provided either pomalidomide or a combination of this drug with low dose of dexamethasone.

The experiment was conducted on 221 patients with relapse or refractory melanoma. The goal of the experiment was to measure the objective response rate.

The trial produced results that the patients who received pomalidomide alone had 7.4% of objective response rate. Ones, who were given the combination of two, met a response rate of 29.2%.

The usual side effects of the drug are neutropenia, anemia, fatigue and weakness, constipation, diarrhea, thrombocytopenia, upper respiratory tract infections, back pain, and fever.

The drug pomalidomide exhibits on its box a warning that says that pregnant woman must refrain from consuming it. It can pose threat by increased blood clots in the body.

According to MD, of the FDA Center for Drug Evaluation and Research, Richard Pazdur, "Treatment for multiple myeloma is tailored to meet individual patients' needs and today's approval provided an additional treatment option for patients who have not responded to other drugs."